The disparity in use of GLP-1 RAs between high-income and low-income people with type 2 diabetes is further exacerbated by the ongoing global shortage of semaglutide and dulaglutide, partially driven by increased off-label use of these drugs for weight loss [37, 38]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.